Suggested remit: to appraise the clinical and cost effectiveness of acoramidis within its marketing authorisation for treating transthyretin-related amyloidosis cardiomyopathy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6354
Provisional Schedule
- Expected publication:
- 08 January 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Bayer (acoramidis)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Amyloidosis UK
- Cardiomyopathy UK
- Gene People
- Kidney Research UK
- Professional groups
- British Association for the Study of the Liver
- Royal College of Ophthalmologists
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Pfizer (tafamidis) (Confidentiality agreement signed, participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 July 2025 | Invitation to participate |
| 06 March 2025 - 03 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6354 |
| 06 March 2025 | In progress. Scoping commenced. |
| 22 May 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early June 2025 when we will write to you about how you can get involved. |
| 13 September 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual